In murine epithelial ovarian cancer, pairing PD-1 blockade with agents targeting immunometabolic pathways (e.g., tryptophan metabolism) reduced immunosuppressive CD39+PD-1+ cells and improved antitumor immunity (87). Here, ENTPD1 is linked to ovarian carcinoma.